2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A population pharmacokinetic model based on HPTN 077 of long-acting injectable cabotegravir for HIV PrEP.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cabotegravir delivered as a long-acting intramuscular injection has shown superior efficacy to oral tenofovir-emtricitabine as pre-exposure prophylaxis (PrEP) for HIV. Cabotegravir pharmacokinetics (PK), like those of other long-acting depot preparations, exhibit variability between individuals and between injection occasions. The aim of this study is to describe the population pharmacokinetics of long-acting cabotegravir (CAB-LA).

          Related collections

          Author and article information

          Journal
          Br J Clin Pharmacol
          British journal of clinical pharmacology
          Wiley
          1365-2125
          0306-5251
          Oct 2022
          : 88
          : 10
          Affiliations
          [1 ] School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, NY, USA.
          [2 ] Department of Medicine, Division of Clinical Pharmacology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
          [3 ] Department of Psychiatry, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
          [4 ] Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
          [5 ] Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
          [6 ] Los Angeles, Center for Clinical AIDS Research and Education, The University of California, Los Angeles, CA, USA.
          [7 ] FHI 360, Durham, NC, USA.
          [8 ] GlaxoSmithKline, Research Triangle Park, NC, USA.
          [9 ] Department of Medicine, Division of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
          Article
          NIHMS1874649
          10.1111/bcp.15477
          10077525
          35949044
          6070da94-f386-4732-86d7-9cbe755ed7a6
          History

          pharmacometrics,infectious diseases,antiretrovirals,HIV/AIDS

          Comments

          Comment on this article